Inhibitor Strength Analysis

Inhibitor Strength Analysis

Inhibitor Strength Distribution
Clinical Significance Guide
Strong Inhibitor: Causes ≥5-fold increase in AUC or ≥80% decrease in clearance
Moderate Inhibitor: Causes ≥2-fold but <5-fold increase in AUC
Weak Inhibitor: Causes ≥1.25-fold but <2-fold increase in AUC
Top Drugs - Strong Inhibitors
DrugInteractions
amitriptyline 38
abemaciclib 30
alfentanil 30
astemizole 30
acalabrutinib 30
amlodipine 30
atorvastatin 30
boceprevir 30
alectinib 30
apixaban 30
Top Drugs - Moderate Inhibitors
DrugInteractions
amitriptyline 35
doxepin 26
venlafaxine 25
propranolol 22
citalopram 21
ponatinib 21
vilazodone 21
tamoxifen 21
escitalopram 21
rucaparib 18
Top Drugs - Weak Inhibitors
DrugInteractions
amitriptyline 31
doxepin 30
venlafaxine 24
propranolol 22
clomipramine 21
imipramine 21
clopidogrel 20
ospemifene 20
phenytoin 19
voriconazole 19
Top Enzymes by Inhibitor Strength
Enzyme Strong Moderate Weak Total
3A457 2655 1416 177 9204
2D6 240 540 240 2369
2C19 88 176 480 919
2C9 34 136 269 541
1A2 36 36 216 504
0 0 0 240
2B6 15 15 30 165
2C8 12 47 37 156
2E1 12 0 0 36
enzyme 0 0 0 1
Clinical Recommendations
Strong Inhibitors
  • Avoid co-administration if possible
  • Consider alternative medications
  • Reduce dose of sensitive substrate drugs
  • Monitor for adverse effects closely
Moderate Inhibitors
  • Use with caution
  • Monitor therapeutic response
  • Consider dose adjustment
  • Regular patient monitoring
Weak Inhibitors
  • Generally safe for co-administration
  • Routine monitoring sufficient
  • No dose adjustment typically needed
  • Low risk of clinically significant interactions
Back to Interactions
✍️ Author: Ahmed Mohmad Rashyd Musleh Registered Staff Nurse